Target Name: VTI1B
NCBI ID: G10490
Review Report on VTI1B Target / Biomarker Content of Review Report on VTI1B Target / Biomarker
VTI1B
Other Name(s): Vesicle-associated soluble NSF attachment protein receptor | vesicle transport through interaction with t-SNAREs 1B | Vti1-rp1 | VTI1-LIKE | VTI1B_HUMAN | vti1-rp1 | vesicle-associated soluble NSF attachment protein receptor | VTI1L1 | Vesicle transport v-SNARE protein Vti1-like 1 | VTI2 | VTI1L | v-SNARE | vesicle transport v-SNARE protein Vti1-like 1 | VTI1 | Vesicle transport through interaction with t-SNAREs 1B | V-SNARE | Vesicle transport through interaction with t-SNAREs homolog 1B

VTI1B: A Potential Drug Target and Biomarker for Vesicle-Associated Soluble NSF Attachment Protein Receptor

Introduction

Vesicle-associated soluble NSF attachment protein receptor (VASPR) is a protein that plays a crucial role in the regulation of cellular processes such as inflammation, migration, and survival. The VASPR is a member of the NSF (Neutrophil Systemic Foundation) family of proteins , which are involved in various cellular processes, including inflammation and tissue repair. VASPR is expressed in various tissues and cells throughout the body, including the brain, lungs, heart, kidneys, and intestines.

Recent studies have identified VASPR as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. VASPR has also been shown to be involved in various signaling pathways, including the NF-kappa pathway, which is involved in cell growth, differentiation, and survival.

Drug Target Potential

VASPR is a potential drug target due to its involvement in various signaling pathways. Many drugs that are currently in use for various diseases have been shown to modulate the activity of VASPR. For example, inhibitors of the NF-kappa pathway, which is involved in cell growth and survival, have been shown to reduce the expression of VASPR. Additionally, inhibitors of the Fc portion of the antibody have been shown to increase the expression of VASPR.

Biomarker Potential

VASPR has also been shown to be a potential biomarker for various diseases. The expression of VASPR has been shown to be increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, the activity of VASPR has been shown to be involved in the regulation of cellular processes, including cell growth, migration, and survival.

Expression and Localization

VASPR is a cytoplasmic protein that is expressed in various tissues and cells throughout the body. It is primarily expressed in the brain, where it is involved in the regulation of neurotransmitter signaling. VASPR is also expressed in other tissues, including the lungs, heart, kidneys, and intestines, where it is involved in the regulation of various physiological processes.

VASPR is primarily localized to the cytoplasm of the cells in which it is expressed. It is not known to be involved in any intracellular signaling pathways.

Conclusion

In conclusion, VASPR is a protein that has been identified as a potential drug target and biomarker for various diseases. Its involvement in various signaling pathways, including the NF-kappa pathway, makes it a promising target for small molecules that can modulate its activity. Additionally, its expression in various tissues and cells throughout the body makes it a potential biomarker for various diseases. Further research is needed to fully understand the role of VASPR in disease progression and the development of new treatments.

Protein Name: Vesicle Transport Through Interaction With T-SNAREs 1B

Functions: V-SNARE that mediates vesicle transport pathways through interactions with t-SNAREs on the target membrane. These interactions are proposed to mediate aspects of the specificity of vesicle trafficking and to promote fusion of the lipid bilayers. May be concerned with increased secretion of cytokines associated with cellular senescence

The "VTI1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VTI1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53